logo
Goldman Sachs is pulling back risk as it braces for more fallout from 'disruptive policy' shifts: COO

Goldman Sachs is pulling back risk as it braces for more fallout from 'disruptive policy' shifts: COO

Goldman Sachs is battening down the hatches as it braces for a wave of volatility resulting from disruptive policy changes in Washington.
"I would say, at the moment, we're relatively defensively positioned," the bank's President and COO, John Waldron, said at a conference on Thursday. "We've got heavy liquidity. We've got significant capital buffers. And we're running more muted risk in certain and important pockets in the firm."
Trump's tariffs and trade war pronouncements have roiled markets in recent weeks, exposing Wall Street to more stressors than many traders and dealmakers anticipated when the former New York businessman returned to power earlier this year.
On Thursday, Waldron said tariffs are just one piece of the puzzle — and no longer as concerning as they were when they were rolled out.
"We're moving, as we said, towards more manageable tariff levels," Waldron said, adding, "I think we're likely to avoid a recession with this baseline set of facts."
Even if the president's tariff wars are quickly resolved, the barrage of seismic policy shifts will likely continue, he said.
"The Trump administration is definitely disrupting a lot of what would be the conventional wisdom of how US policymaking traditionally goes," he said at the annual Bernstein Strategic Decisions conference in New York.
"You see first-order impacts right in front of you," he said, referring to the tariffs. "The second- and third-order impacts take longer to work their way through markets. And so we're watching carefully for the second- and third-order impacts, which is another reason why we run a little bit higher buffer and a little bit more cautiously in an environment like this."
"So we're going to learn a lot more, and it's going to be volatile," he said. "I think we're just got to live with that volatility for some time."
Waldron pointed to two cues that the firm is watching. The first, he said, is leverage in the public sector. Governments have much less wiggle room to inject stimulus into battered economies to maneuver out of tough fiscal positions, diminishing their ability to fend off economic shocks.
"I think coming out of COVID, the public sector stimulus from governments around the world to rejuvenate the economy was really, really important," he said. "We're starting to see some elements of that public sector leverage play through. There's a lot less fiscal headroom in the world today than there was back when we were coming through COVID and a pretty peaceful environment."
He also pointed to something the firm is terming "lowflation" — that is, its forecast that, because of tariffs, the US should ready itself for "short- to immediate-term slower growth" and "higher inflation." He said Goldman's research showed that the best case scenario for effective tariffs would be between 10% to 15%, still a significant uptick from pre-Trump administration levels.
In good news, Waldron said that US consumers had continued to exhibit "tremendous resilience" in the face of these headwinds, and that the firm's pipeline of forthcoming transactions remained strong.
"Not surprisingly, the second quarter is not quite as strong from an activity level as the first quarter, given the macro environment we talked about at the beginning of this conversation," he said, adding, "But in investment banking, our engagement levels are actually still very good despite the uncertainty and the volatility our pipelines remain quite strong."
"When you have this kind of volatility," he said, "you just fundamentally have a harder time prosecuting transactions that may be in your pipeline."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'
Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'

Newsweek

time23 minutes ago

  • Newsweek

Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Marjorie Taylor Greene has spoken out against a new COVID-19 vaccine being approved in the United States, saying the move is "not MAHA at all." Why It Matters Health Secretary Robert F. Kennedy Jr. is facing repeated backlash for some of his positions on health and medicine, including from people who would ordinarily support him. In May, prominent members of the Make America Great Again movement, including Nicole Shanahan, Kennedy's former presidential running mate, and media personality Laura Loomer, spoke out against Kennedy Jr.'s pick for U.S. Surgeon General Casey Means. In March, Kennedy Jr. sparked anger from anti-vax activists when he called on parents to "consult with their healthcare providers to understand their options to get the MMR vaccine," with one saying he is "no different than Fauci." Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. AP What To Know The U.S. Food and Drug Administration (FDA) gave the green light for mNEXSPIKE (mRNA-1283), Moderna's new lower-dose COVID-19 vaccine, on May 31. Greene, the U.S. representative for Georgia's 14th congressional district, shared Moderna's post about the recent approval with the caption: "Not MAHA at all!!! Unreal." Not MAHA at all!!! Unreal. — Rep. Marjorie Taylor Greene🇺🇸 (@RepMTG) June 1, 2025 She was referring to Kennedy Jr.'s movement Make America Healthy Again, whose mission is to "aggressively combat the critical health challenges facing our citizens, including the rising rates of mental health disorders, obesity, diabetes, and other chronic diseases." Newsweek has contacted the United States Department of Health and Human Services outside of office hours, via email, for comment. The new vaccine is set to be used for adults 65 or older or people between the ages of 12 and 64 with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC). Approval for the jab is "based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial which enrolled approximately 11,400 participants aged 12 years and older," Moderna says. It comes after Kennedy Jr. announced that the CDC is no longer encouraging COVID-19 vaccines for pregnant women and healthy children, marking a shift in federal public health guidance. What People Are Saying Chief Executive Officer of Moderna Stéphane Bancel said in a statement: "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." Kennedy Jr. said about the new CDC guidance: "I couldn't be more pleased to announce that as of today the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule." What Happens Next The new vaccine is expected to be ready for those eligible to take it in time for the 2025-2026 respiratory virus season. You should not get mNEXSPIKE if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (an mRNA vaccine for preventing COVID-19) or any Moderna COVID-19 vaccine or to any ingredient in these vaccines, the company warns.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store